Home/Pipeline/NTRX-07

NTRX-07

Alzheimer's Disease

Phase 2Active

Key Facts

Indication
Alzheimer's Disease
Phase
Phase 2
Status
Active
Company

About NeuroTherapia

NeuroTherapia is a private, clinical-stage biotech advancing an oral, small molecule CB2 receptor agonist, NTRX-07, to treat neuroinflammatory conditions like Alzheimer's Disease (AD) and neuropathic pain. The company, a Cleveland Clinic spin-out founded in 2009, has completed Phase 1 studies showing safety and a trend toward cognitive improvement in AD, with a Phase 2 trial planned for 2024. NeuroTherapia is backed by venture capital, foundations, and state grants, positioning it to explore a novel anti-inflammatory mechanism that could complement existing protein-targeting therapies in the challenging CNS market.

View full company profile

About NeuroTherapia

NeuroTherapia is a private, clinical-stage biotech advancing an oral, small molecule CB2 receptor agonist, NTRX-07, to treat neuroinflammatory conditions like Alzheimer's Disease (AD) and neuropathic pain. The company, a Cleveland Clinic spin-out founded in 2009, has completed Phase 1 studies showing safety and a trend toward cognitive improvement in AD, with a Phase 2 trial planned for 2024. NeuroTherapia is backed by venture capital, foundations, and state grants, positioning it to explore a novel anti-inflammatory mechanism that could complement existing protein-targeting therapies in the challenging CNS market.

View full company profile

Other Alzheimer's Disease Drugs

DrugCompanyPhase
NUZ-001Neurizon TherapeuticsPreclinical
ALZN002Alzamend NeuroPreclinical
P021Phanes BiotechPreclinical
PB43DPhanes BiotechPreclinical
UB-311VaxxinityPhase 2
LecanemabBioArcticLaunched
BAN2401BioArcticPreclinical
Undisclosed Programsjohnson-and-johnson-innovative-medicinePipeline
MK-6240 (florquinitau)Lantheus Medical ImagingRegulatory Filing
NAV-4694 (flutafuranol)Lantheus Medical ImagingPhase 3
LNTH-2620/PI-2620Lantheus Medical ImagingPhase 3
itMSCsStemedica Cell TechnologiesClinical Development